Increased risk of chronic obstructive pulmonary disease in patients with systemic lupus erythematosus: A population-based cohort study

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Shen, Te Chun ^a,b   Lin, Cheng Li ^a,c   Chen, Chia Hung ^a   Tu, Chih Yen ^a   Hsia, Te Chun ^a   Shih, Chuen Ming ^a   Hsu, Wu Huei ^a   Chang, Yen Jung ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Chu Shang Show Chwan Hospital   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN; TERMINAL DISEASE; AGED; COMPLICATION; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; YOUNG ADULT;

AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; TAIWAN; YOUNG ADULT;

EID: 84898714629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091821     Document Type: Article

References (36)

1. Pons-Estel GJ, Alarco'n GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthr Rheum 39: 257-68.
2. Fessel WJ (1988) Epidemiology of systemic lupus erythematosus. Rheum Dis Clin N Am 14: 15-23.
3. Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL (2013) Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol Int DOI: 10.1007/s00296-012-2643-6.
4. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-65.
5. Mannino DM, Buist AS (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-73. (Pubitemid 47321908)
6. Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, et al. (2002) Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 166: 1078-83. (Pubitemid 35178705)
7. Hagstad S, Ekerljung L, Lindberg A, Backman H, Rönmark E, et al. (2012) COPD among non-smokers - Report from the Obstructive Lung Disease in Northern Sweden (OLIN) studies. Respir Med 106: 980-8.
8. Packard TA, Li QZ, Cosgrove GP, Bowler RP, Cambier JC (2013) COPD is associated with production of autoantibodies to a broad spectrum of selfantigens, correlative with disease phenotype. Immunol Res 55: 48-57.
9. Bieber V, Cohen AD, Freud T, Agmon-Levin N, Gertel S, et al. (2013) Autoimmune smoke and fire - coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Immunol Res 56: 261-6.
10. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, et al. (2008) Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 156-63.
11. Karayama M, Inui N, Suda T, Nakamura Y, Nakamura H, et al. (2010) Antiendothelial Cell Antibodies in Patients With COPD. Chest 138: 1303-8.
12. Kirkham PA, Caramori G, Casolari P, Papi AA, Edwards M, et al. (2011) Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184: 796-802.
13. Kuo YB, Chang CA, Wu YK, Hsieh MJ, Tsai CH, et al. (2010) Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. Immunol Lett 128: 131-6.
14. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, et al. (2007) Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13: 567-9. (Pubitemid 46828488)
15. Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, et al. (2009) Novel autoantigens immunogenic in COPD patients. Respir Res 10: 20.
16. Núñez B, Sauleda J, Antó JM, Julià MR, Orozco M, et al. (2011) Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 183: 1025-31.
17. Cheng TM (2009) Taiwan's national health insurance system: high value for the dollar. Six Countries, Six Reform Models: Their Healthcare Reform: Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. Hackensack, NJ: World Scientific 171-204.
18. Shen TC, Tu CY, Lin CL, Wei CC, Li YF (2014) Increased risk of asthma in patients with systemic lupus erythematosus. Am J Respir Crit Care Med 189: 496-9.
19. Shen TC, Lin CL, Wei CC, Tu CY, Li YF (2014) The risk of asthma in rheumatoid arthritis: a population-based cohort study. QJM Jan 20.
20. Health Promotion Administration, Ministry of Health and Welfare of Taiwan website. Available: http://www.hpa.gov.tw/BHPNet/Web/HealthTopic/Topic.aspx?id= 200712250024. Accessed 2014 Feb 18.
21. Freemer MM, King TE Jr, Criswell LA (2006) Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 65: 581-4.
22. Majka DS, Holers VM (2006) Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 65: 561-3.
23. Drenkard C, Rask KJ, Easley KA, Bao G, Lim SS (2013) Primary preventive services in patients with systemic lupus erythematosus: study from a population-based sample in Southeast U.S. Semin Arthritis Rheum 43: 209-16.
24. Petri M, Thompson E, Abusuwwa R, Huang J, Garrctt E (2001) BALES: the Baltimore Lupus Environmental Study. Arthritis Rheum 44 Suppl 9: S331.
25. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS (2001) Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. J Rheumatol 28: 2653-6. (Pubitemid 33135650)
26. Reidenberg MM, Drayer DE, Lorenzo B, Strom BL, West SL, et al. (1993) Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 36: 971-3. (Pubitemid 23201112)
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-7. (Pubitemid 13221242)
28. The Global Initiative for Chronic Obstructive Lung Disease website. Available: http://www.goldcopd.org/. Accessed 2013 Nov 20.
29. Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34: J258-65.
30. Zifman E, Amital H, Gilburd B, Shoenfeld Y (2008) Antioxidants and smoking in autoimmune disease-opposing sides of the seesaw? Autoimmun Rev 8: 165-9.
31. Carmi G, Amital H (2011) The geoepidemiology of autoimmunity: capsules from the 7th International Congress on Autoimmunity, Ljubljana, Slovenia, May 2010. Isr Med Assoc J 13: 121-7.
32. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G (2002) Risk factors for developing systemic lupus erythematosus: a casecontrol study in southern Sweden. Rheumatology [Oxford] 41: 563-71. (Pubitemid 34567188)
33. Vermeulen A (1993) Environment, human reproduction, menopause, and andropause. Environ Health Perspect 101 (Suppl2): 91-100.
34. Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, et al. (2008) Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 10: 799-811. (Pubitemid 351225898)
35. Suzuki M, Betsuyaku T, Nagai K, Fuke S, Nasuhara Y, et al. (2008) Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. Inhal Toxicol 20: 349-59. (Pubitemid 351323659)
36. MacRedmond RE, Greene CM, Dorscheid DR, McElvaney NG, O'Neill SJ (2007) Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res 8: 84.